Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company's products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company's customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Life Sciences Tools & Services
- Exchange: NASDAQ
- Symbol: ILMN
- CUSIP: 45232710
- Previous Close: $161.01
- 50 Day Moving Average: $160.70
- 200 Day Moving Average: $153.17
- 52-Week Range: $119.37 - $186.88
- Trailing P/E Ratio: 52.12
- Foreward P/E Ratio: 37.30
- P/E Growth: 3.87
- Market Cap: $23.41B
- Outstanding Shares: 146,300,000
- Beta: 0.79
- Net Margins: 19.31%
- Return on Equity: 22.89%
- Return on Assets: 12.37%
Companies Related to Illumina:
- Debt-to-Equity Ratio: 0.46%
- Current Ratio: 3.29%
- Quick Ratio: 2.86%
What is Illumina's stock symbol?
Illumina trades on the NASDAQ under the ticker symbol "ILMN."
Where is Illumina's stock going? Where will Illumina's stock price be in 2017?
23 brokerages have issued 12-month target prices for Illumina's stock. Their predictions range from $100.00 to $200.00. On average, they anticipate Illumina's share price to reach $150.80 in the next year.
When will Illumina announce their earnings?
Illumina is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.
What are analysts saying about Illumina stock?
Here are some recent quotes from research analysts about Illumina stock:
According to Zacks Investment Research, "Illumina witnessed a robust share price movement as compared to the Zack Categorized Medical-Biomed/Genetics subindustry trend in the past six months. However a dismal estimate revision trend indicates looming concerns ahead. The company posted mixed third-quarter results with earnings surpassing the Zacks Consensus Estimate while revenues missed the mark as well as the company’s expectations. On a positive note, the company performed well in the Asia Pacific and Europe. There was also robust sequencing and array consumable growth in the third quarter. However narrow EPS guidance for the full year adds to woes. Revenues in the Americas witnessed a slower pace of growth. Overall, the year-over-year fall in sequencing instrument revenue due to the challenging HiSeq X comparison marred the entire performance." (12/13/2016)
Cantor Fitzgerald analysts commented, "ILMN remains confident that weakness was due to internal execution and not PACB Sequel launch. Subsequent to the preannouncement, ILMN gained greater insight into the drivers behind the HiSeq weakness, including the timing of funding, assessing NextSeqs, and delays in deliveries (see exhibit 2). The company is confident that few, if any, of these are related to customers using funding to purchase PACB’s Sequel." (5/4/2016)
Morgan Stanley analysts commented, "We expected the slowing to emerge more slowly given the healthy growth we see in sequencing volumes in the research channel (Signs of Improvement in the Research Channel (06 Signs of Improvement in the Research Channel (06 Apr) Apr)) and indications of new user demand in our fall ’15 survey. We expect our upcoming spring ’16 sequencing survey to find weaker new user demand." (4/19/2016)
Who owns Illumina stock?
Illumina's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (12.78%), Edgewood Management LLC (4.52%), Sands Capital Management LLC (3.89%), FMR LLC (0.56%), Frontier Capital Management Co. LLC (0.33%) and TCW Group Inc. (0.28%). Company insiders that own Illumina stock include A Blaine Bowman, Charles Dadswell, Christian O Henry, Daniel Bradbury, David R Walt, Gerald Moeller, Jay T Flatley, Karin Eastham, Marc Stapley, Michel Bouchard, Mostafa Ronaghi, Nicholas Naclerio, Omead Ostadan, Paul L Bianchi, Richard Klausner, Robert S Epstein and Roy A Whitfield.
Who sold Illumina stock? Who is selling Illumina stock?
Illumina's stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Credit Agricole S A, TCW Group Inc., Orbimed Advisors LLC, Capital Guardian Trust Co., FMR LLC, Marshall Wace LLP and Fiera Capital Corp. Company insiders that have sold Illumina stock in the last year include A Blaine Bowman, Charles Dadswell, Christian O Henry, Daniel Bradbury, David R Walt, Jay T Flatley, Karin Eastham, Marc Stapley, Nicholas Naclerio, Omead Ostadan, Paul L Bianchi, Robert S Epstein and Roy A Whitfield.
Who bought Illumina stock? Who is buying Illumina stock?
Illumina's stock was purchased by a variety of institutional investors in the last quarter, including Edgewood Management LLC, Viking Global Investors LP, Asset Management One Co. Ltd., Janus Capital Management LLC, Baillie Gifford & Co., ARK Investment Management LLC, Everett Capital Advisors UK LLP and Russell Investments Group Ltd..
How do I buy Illumina stock?
Shares of Illumina can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Illumina stock cost?
One share of Illumina stock can currently be purchased for approximately $160.00.